Tibial IMN Vs. Tibial Micromotion IMN
Launched by UNIVERSITY OF CHICAGO · May 8, 2025
Trial Information
Current as of September 10, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is comparing two different methods for fixing tibial fractures, which are breaks in the shinbone. One method uses a standard intramedullary nail, while the other uses a special type called a micromotion nail. The goal of the study is to find out if these two methods lead to different outcomes in terms of healing and complications after surgery. Currently, there isn't enough information to know which method might be better, as this specific comparison has not been studied before.
To be eligible for the trial, participants must be at least 18 years old and have an unstable tibial fracture that requires surgery. Certain patients, such as those with stable fractures or existing infections, cannot join the study. If you participate, you can expect to be randomly assigned to one of the two treatment groups and will be monitored for healing, complications, pain levels, and overall function after the surgery. This research aims to provide valuable insights that could improve treatment options for future patients with similar injuries.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age 18 or older
- • 2. Unstable tibial fracture recommended for surgical intervention
- Exclusion Criteria:
- • 1. Patients not meeting inclusion criteria (Stable fracture patterns)
- • 2. Previously non-ambulatory patients
- • 3. Delayed presentation of fracture (\>4 weeks)
- • 4. Fractures that the treating surgeon indicates requires additional fixation strategies to achieve stability
- • 5. Patients with an active infection or wound at the surgical site
- • 6. Utilizing worker's compensation at the time of screening
- • 7. Any previous ligament or fracture surgery on the index site
- • 8. Inflammatory rheumatic disease or other rheumatic disease
- • 9. Immune compromised patients (hepatitis, HIV, etc.)
- • 10. Non-English-speaking patients
- • 11. Unwilling or unable to participate or follow study protocol
About University Of Chicago
The University of Chicago is a prestigious research institution renowned for its commitment to advancing medical science through innovative clinical trials. With a robust infrastructure that supports multidisciplinary collaboration, the University actively engages in cutting-edge research across various therapeutic areas. Its dedicated team of experienced investigators and state-of-the-art facilities enable the University of Chicago to conduct rigorous clinical studies aimed at improving patient outcomes and translating scientific discoveries into tangible healthcare solutions. The institution prioritizes ethical standards and patient safety, ensuring that all trials adhere to the highest regulatory guidelines and best practices in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported